May 25, 2020
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for Chugai Pharmaceutical’s cancer agent Avastin (bevacizumab) and Daiichi Sankyo’s Alzheimer’s drug Memary (memantine), a move likely to trigger label changes in the near future. According to...read more